Levoprolin (Levofloxacin)

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This inhibition prevents bacterial DNA from unwinding and resealing, leading to bacterial cell death and a broad‑spectrum bactericidal effect.

The exact dose of Levoprolin is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. No fixed regimen is provided here.

Safety of levofloxacin during pregnancy and lactation has not been established. It should be used only when the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To order Levoprolin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Levoprolin (levofloxacin) offers a once‑daily dosing option and a broad spectrum of activity against both Gram‑positive and Gram‑negative organisms, similar to other fluoroquinolones. Compared with older agents like ciprofloxacin, levofloxacin has enhanced activity against Streptococcus pneumoniae and may achieve higher tissue concentrations in respiratory infections.

Levoprolin must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Prior to use, inspect the solution for particulate matter or discoloration and follow aseptic techniques for preparation and administration.

Levoprolin is given by intravenous infusion. The solution is typically diluted with compatible IV fluids and infused over a period recommended by the prescriber, often 30‑60 minutes, depending on the clinical situation and patient tolerance.

Serious risks associated with Levoprolin include tendon rupture (especially Achilles), QT interval prolongation leading to arrhythmias, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, and Clostridioides difficile‑associated colitis. Patients should be monitored promptly for any of these events.

Levoprolin should be avoided in individuals with a known hypersensitivity to levofloxacin or other fluoroquinolones, a history of tendon disorders related to fluoroquinolone use, prolonged QT interval, or severe renal impairment without appropriate dose adjustment. Caution is also advised for patients taking concurrent corticosteroids or drugs that affect cardiac conduction.